Related Experiment Video

Updated: Apr 4, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Ridaifen G, tamoxifen analog, is a potent anticancer drug working through a combinatorial association with multiple

Kentaro Ikeda1, Shinji Kamisuki1, Shoko Uetake2

  • 1Department of Applied Biological Science, Tokyo University of Science, Chiba, Japan.

Bioorganic & Medicinal Chemistry
|August 29, 2015
PubMed

Insights

Ridaifen-G, a tamoxifen analog, inhibits cancer cell growth by targeting calmodulin, hnRNP A2/B1, and ZNF638 proteins. Its unique mechanism differs from tamoxifen, offering new therapeutic insights.

Area of Science:

  • Molecular biology
  • Pharmacology
  • Cancer research

Background:

  • Ridaifen-G (RID-G) is a synthesized tamoxifen analog with demonstrated potent anticancer activity.
  • Unlike tamoxifen, RID-G's mechanism of action is suggested to be distinct, involving pathways beyond the estrogen receptor.
  • Understanding RID-G's molecular targets is crucial for elucidating its therapeutic potential.

Purpose of the Study:

  • To investigate the molecular mechanism of action of Ridaifen-G (RID-G).
  • To identify the direct protein targets of RID-G responsible for its growth inhibitory effects.
  • To correlate cellular response to RID-G with gene expression profiles.

Main Methods:

  • Development of a novel chemical genetic approach combining phage display screening.
  • Statistical analysis of drug potency and gene expression profiles across 39 cancer cell lines.
  • Identification of candidate RID-G protein targets through integrated analysis.

Main Results:

  • Three proteins were identified as candidate direct targets of RID-G: calmodulin (CaM), heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2/B1), and zinc finger protein 638 (ZNF638).
  • Cancer cell lines susceptible to RID-G exhibited similar expression profiles of these identified target genes.
  • These findings suggest a novel molecular pathway for RID-G's anticancer activity.

Conclusions:

  • RID-G exerts its growth inhibitory effects by engaging CaM, hnRNP A2/B1, and ZNF638.
  • The study elucidates a distinct mechanism of action for RID-G compared to tamoxifen.
  • RID-G represents a promising therapeutic agent with a unique molecular signature for cancer treatment.
Keywords:
Anticancer drugPhage displayTamoxifenTarget identification

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K
Identification Of Erythromyeloid Progenitors And Their Progeny In The Mouse Embryo By Flow Cytometry08:59

Identification Of Erythromyeloid Progenitors And Their Progeny In The Mouse Embryo By Flow Cytometry

Published on: July 17, 2017

13.7K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K